Oncology Newswire

Oncology Newswire

Comprehensive Real-Time News Feed for Oncology.

Results 1 - 20 of 20,148 in Oncology

  1. Roche announces Fda approval of new Ventana PD-L1 assayRead the original story w/Photo

    22 min ago | Medical News

    Roche today announced approval of the VENTANA PD-L1 Assay by the US Food and Drug Administration as a complementary diagnostic to provide PD-L1 status on patients who are considering treatment with the FDA approved Roche immunotherapy TECENTRIQ for metastatic urothelial cancer . This test is the first to evaluate patient PD-L1 status using immune cell staining and scoring within the tumor microenvironment, providing clinicians with information that may guide immunotherapy decisions.

    Comment?

  2. Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class InnovationRead the original story

    33 min ago | Emailwire.com

    ... impact future treatment options? 52% of pipeline products act on a first-in-class target, which is higher than the oncology and industry averages. Read All Pharmaceutical Market Research Reports @ http://www.r ...

    Comment?

  3. Frontier Pharma: Versatile Innovation in Oncology - Identifying and...Read the original story

    33 min ago | Emailwire.com

    ResearchMoz added Latest Research Report titled " Frontier Pharma: Versatile Innovation in Oncology - Identifying and Commercializing Versatile First-in-Class Innovation " to it's Large Report database. The oncology therapy area comprises a large and diverse range of indications, encompassing virtually all sites and tissues in the human body.

    Comment?

  4. Women of Distinction Magazine Selects Lida DalBello-Dighton as a...Read the original story w/Photo

    1 hr ago | 24-7 Press Release

    MARKHAM, ON, July 30, 2016 /24-7PressRelease/ -- Lida DalBello-Dighton, Owner and Optimal Health Facilitator of Divine Strategies for Wellness, has been recognized as a Distinguished Professional in her field through Women of Distinction Magazine. Lida DalBello-Dighton will be featured in an upcoming edition of the Women of Distinction Magazine in 2016/2017.

    Comment?

  5. Beigene Ltd (BGNE) Stock Price Down 4.2%Read the original story w/Photo

    2 hrs ago | Daily Political

    ... company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton's tyrosine ...

    Comment?

  6. Fate Therapeutics Inc. (FATE) Trading 4.5% HigherRead the original story w/Photo

    2 hrs ago | Daily Political

    ... cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, ...

    Comment?

  7. Hall joins CARTI teamRead the original story w/Photo

    4 hrs ago | Log Cabin Democrat

    ... finest quality cancer treatment." Prior to arriving at CARTI, Hall recently completed his fellowship in hematology/oncology at Wake Forest Baptist Medical Center in Winston-Salem, N.C. A magnum cum laude graduate of the University of Arkansas with a ...

    Comment?

  8. Merrimack Pharmaceuticals Inc. (MACK) Sees Large Volume IncreaseRead the original story w/Photo

    4 hrs ago | Daily Political

    ... medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. Its therapeutic oncology candidates in clinical development include MM-398, MM-302, MM-121, MM-141 and MM-151.

    Comment?

  9. NovoCure Ltd. (NVCR) Sees Large Volume IncreaseRead the original story

    4 hrs ago | Daily Political

    ... a new position in NovoCure during the fourth quarter worth $9,619,000. NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a therapy called TTFields for the treatment of solid tumor cancers. TTFields is a ...

    Comment?

  10. Local Fire Rescue Paramedic hospitalized in Jacksonville cancer unitRead the original story w/Photo

    5 hrs ago | Historic City News

    ... The doctors determined that in-patient treatment should begin immediately, so Accorti has been placed on the Oncology floor at Baptist/MD Anderson Cancer Center. He will remain in the hospital for at least six weeks while receiving aggressive daily ...

    Comment?

  11. Colombia strengthens its hospital care selection to attract more foreign patientsRead the original story w/Photo

    5 hrs ago | Caribbean News Now!

    ... the past two decades Colombia has treated international patients seeking ophthalmology, cardiology, odontology and oncology treatments among other specialties all with the highest-quality and trained medical personnel. There are several advantages ...

    Comment?

  12. Collaboration - and fruit flies - suggest potential strategy for colon cancer in CU studyRead the original story w/Photo

    6 hrs ago | Denver Post

    ... of colon cancer, but other varieties as well. "Potentially," cautioned Joaquin Espinosa, co-leader of the molecular oncology program at CU's Cancer Center and scientific director of the Linda Crnic Institute for Down Syndrome. "With many cancers you ...

    Comment?

  13. Ariad Pharmaceuticals Inc. (ARIA) Rating Reiterated by Jefferies GroupRead the original story w/Photo

    6 hrs ago | AmericanBankingNews.com

    ... has a consensus rating of "Buy" and an average target price of $9.19. ARIAD Pharmaceuticals, Inc (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company's product pipeline ...

    Comment?

  14. Cerulean Pharma Inc. (CERU) Trading Up 6.5%Read the original story w/Photo

    7 hrs ago | Daily Political

    ... Cerulean Pharma Inc. will post ($1.80) EPS for the current fiscal year. Cerulean Pharma Inc is a clinical-stage, oncology-focused company. The Company applies its Dynamic Tumor Targeting platform to develop differentiated therapies. Its platform ...

    Comment?

  15. NovoCure Ltd. (NVCR) Price Target Cut to $34.00 by Analysts at JMP SecuritiesRead the original story

    8 hrs ago | AmericanBankingNews.com

    ... NovoCure will post ($1.46) earnings per share for the current fiscal year. NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a therapy called TTFields for the treatment of solid tumor cancers. TTFields is ...

    Comment?

  16. SITC Launches New Initiative Non-Small Cell Lung Cancer Immunotherapy: Advancing HopeaRead the original story w/Photo

    12 hrs ago | PRWeb

    ... across the continuum of cancer care, including Association of Community Cancer Centers, Association of Oncology Social Work, Bonnie J. Addario Lung Cancer Foundation, Cancer Support Community, Lung Cancer Alliance and LUNGevity. SITC encourages ...

    Comment?

  17. New Guidelines Issued for Cancer Patients' Post-Treatment PainRead the original story w/Photo

    Yesterday | MedicineNet

    More people are surviving cancer , but many are left with persistent pain after treatment. New guidelines from the American Society of Clinical Oncology recommend that doctors routinely screen for such pain .

    Comment?

  18. Ariad Pharmaceuticals Inc. (ARIA) Trading 11.5% Higher After Better-Than-Expected EarningsRead the original story w/Photo

    Yesterday | Daily Political

    ... average of $6.78. The stock's market capitalization is $1.82 billion. ARIAD Pharmaceuticals, Inc (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company's product pipeline ...

    Comment?

  19. Cancer Genetics Inc. (CGIX) Lowered to "Hold" at Zacks Investment ResearchRead the original story w/Photo

    9 hrs ago | AmericanBankingNews.com

    ... target cancers, including hematological, urogenital, and HPV-associated cancers. It also offers non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals as well as biopharma ...

    Comment?

  20. Zacks Investment Research Lowers Athersys Inc. (ATHX) to HoldRead the original story w/Photo

    9 hrs ago | Daily Political

    ... for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation/oncology support, ischemic stroke and other indications. " Shares of Athersys (NASDAQ:ATHX) traded up 0.91% on Friday, hitting $2.22. The ...

    Comment?